But the results from the monitoring of large sets of population, always heavy to implement, have been slow. Concerned, however, some practitioners have sounded the alarm, like Prof. Jacob Cukier, former urologist at theNeckerHospital(Paris) who signed in 1997 an article entitled Prostate cancer: a plea for weighting. The benefits of early diagnosis remain to be demonstrated (medical Contest 119-01). He wrote that measure PSA too often led to unnecessary treatment not without consequences. A position he holds today: “The PSA screening does not lengthen the patient’s life, there is qu’allonger of his life sick.” In 2008, other voices have come to support it: those of Dr. In March 2009, two highly anticipated studies, the American PLCO (Prostate, Lung, Colorectal and Ovarian Cancer) and the European ERSPC (European Randomised Study of Screening for Prostate Cancer), were finally published in a refereed journal, The New England Journal of Medicine. Conflicting results, interpreted differently by both sides, failed to get everyone to agree.